It’s healthcare Thursday.
I’m about a week away from sandy beaches, delicious Greek food and a break from the urban jungle. Opa!
I’m out through the Labor Day holiday. If you can’t save all your big healthcare news for September, my colleagues Luisa Beltran andChris Witkowsky will be filling in for me the next couple weeks. Send any urgent news, tips or gossip their way firstname.lastname@example.org or email@example.com.
Based on recent conversations, I expect to return to a busy market as private equity execs return full time and put their latest healthcare investments ripe for picking on the auction block.
One of scale to watch is pharma services company WIRB-Copernicus Group. Read my story to learn who WCG’s backers, Arsenal Capital and Michael Dell’s MSD Partners, have engaged to advise on an upcoming process.
WCG offers compliance- and eClinical-related services to streamline and drive efficiency in the drug research and clinical trial processes.
The compliance, or IRB (independent review board) piece, competes with Advarra, which produced one of healthcare’s deal highlights this summer.
In case you forgot, Genstar Capital put a quick stop to Advarra’s heated sales process in June. The San Francisco firm struck an agreement valuing Advarra at about $1.3 billion only about two weeks after initial bids were submitted. Existing investor Linden Capital reinvested. Read my coverage on the deal for more detail.
One key differentiator between Advarra and WCG: Advarra today is exclusively focused on IRB-type services, whereas WCG is more diversified. The latter also offers eClinical services ranging from study planning and site optimization to patient engagement, as well as market insights for pharma and medical device professionals.